Clinical Trials Browser

Interventional × Breast Neoplasm Female × Fulvestrant × Clear all

NCT03425838 2025-09-19

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasm Female

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasm Female